Keywords: Nucynta, Jansse, Johnson & Johnson, Diabetic peripheral neuropathy

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

Article | 18 May 2012

Print This

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results of an investigational Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in